•  
  •  
  •  
  •  

2025-10-19 21:57:16

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • RPP Infra Projects Ltd wins new orders worth Rs. 125.92 Crores
  • Atishay Ltd receives order worth Rs. 1.97 crore
  • Emirates NBD to acquire majority stake in RBL Bank through primary infusion of ~USD 3bn
  • PNGS Gargi Fashion Jewellery Ltd opens new store at Pajifond, Margao
  • Satchmo Holdings Ltd discharges its total liability as per OTS

Keywords Selected:  USFDA

Stock Report

  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Triamcinolone Acetonide Injectable Suspension USP, 40 mg/mL
  • USFDA approves Turtle Excluder Device, paving way to lift US Ban on Wild-Caught Shrimp Imports from India
  • Biocon Limited updates on GMP inspection by USFDA at its Cranbury, New Jersey facility
  • Lupin gets one observation from USFDA for Somerset, New Jersey manufacturing facility
  • Emcure Pharmaceuticals Ltd completes surveillance inspection by USFDA without any observation
  • Biocon Pharma Ltd in partnership with Carnegie Pharmaceuticals LLC receives USFDA tentative approval for Rifaximin Tablets
  • Zydus receives final approval from USFDA for Deflazacort oral suspension, 22.75 mg/mL
  • FDC Ltd receives USFDA approval for ANDA Pilocarpine Hydrochloride Ophthalmic Solutions
  • Synbiotics Ltd's Amphotericin B Manufacturing Facility receives USFDA approval
  • Sentynl Therapeutics updates on its NDA for CUTX-101
  • Wockhardt Submits New Drug Application to U.S. FDA for Zidebactam-Cefepime for Treatment of Serious GramNegative Infections
  • Lupin receives approval from U.S. FDA for Rivaroxaban for Oral Suspension
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Paroxetine Extended Release Tablets USP, 25 mg and 37.5 mg.
  • Zydus receives EIR for the oncology injectable manufacturing facility in SEZ1, Ahmedabad
  • Jubilant Pharmova announces Completion of Pharmacovigilance Inspection by the USFDA with No Observations
  • Lupin gets 4 observations from USFDA from PAI at Pune Biotech facility
  • USFDA successfully completes inspection at Indoco's API manufacturing facility at Patalganga with zero observations
  • Lupin receives approval from U.S. FDA for Lenalidomide Capsules
  • Lupin receives 6 observations from USFDA for Nagpur Injectable facility
  • Alembic Pharmaceuticals Ltd receives EIR from USFDA for facility at Panelav
  • Update on US FDA Inspection at Sun Pharma Halol Facility
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Phytonadione Injectable Emulsion USP, 1 mg/0.5 mL Single-Dose Prefilled Syringe
  • USFDA conducts product specific pre-approval inspection at Lupin Ltd's Aurangabad facility
  • Closure of USFDA inspection at Zydus' injectable manufacturing plant at Jarod

Latest Post

  • RPP Infra Projects Ltd wins new orders worth Rs. 125.92 Crores
  • Atishay Ltd receives order worth Rs. 1.97 crore
  • Emirates NBD to acquire majority stake in RBL Bank through primary infusion of ~USD 3bn
  • PNGS Gargi Fashion Jewellery Ltd opens new store at Pajifond, Margao
  • Satchmo Holdings Ltd discharges its total liability as per OTS


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024